The Efficacy and Safety of Once-daily Insulin Degludec versus Twice-daily Long-acting Insulin in Adult Type 1 Diabetes Mellitus

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900027613

Enrollment

Unknown

Registered

2019-11-21

Start date

2019-11-25

Completion date

Unknown

Last updated

2019-11-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 1 Diabetes

Interventions

Experimental group A:Insulin glargine or Insulin detemir for 3 months + Insulin Degludec for 3 months

Experimental group B:Insulin Degludec for 6 months

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: (1) Type 1 diabetes patients aged >=18 years old; (2) Treatment with basic insulin (a long-acting insulin analogue including insulin glargine or insulin detemir or NPH)) twice a day and short acting insulin.; (3)HbA1c<=10%; (4)BMI<=30kg/m2.

Exclusion criteria

Exclusion criteria: (1) Women who are pregnant, breastfeeding or may become pregnant; (2) Ptients with a history of acute and chronic infection and tumor; (3) Ptients with cardiovascular disease history within 6 months; (4) Ptients with untreated or uncontrolled severe hypertension; (5) Ptients with recurrent severe hypoglycemia or hypoglycemia coma or hospitalization due to diabetic ketoacidosis within 6 months.

Design outcomes

Primary

Measure	Time frame
Blood sugar before dinner;	—

Countries

China

Contacts

Public ContactLi Yuxiu

Peking Union Medical College Hospital

liyuxiu@medmail.com.cn+86 13581705295

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026